Видео ютуба по тегу Imugene

Imugene’s azer-cel hits 82% response rate in 2025
Imugene’s azer-cel hits 82% response rate in 2025
Imugene (ASX:IMU): Конференция по инвестициям в драгоценные камни ASX, организованная Stock Network
Imugene (ASX:IMU): Конференция по инвестициям в драгоценные камни ASX, организованная Stock Network
Вебинар для инвесторов Imugene — результаты встречи FDA
Вебинар для инвесторов Imugene — результаты встречи FDA
Markets in a Minute: Kairos Minerals and Imugene shine
Markets in a Minute: Kairos Minerals and Imugene shine
Imugene gets FDA backing for azer-cel treatment
Imugene gets FDA backing for azer-cel treatment
Imugene's CAR-T therapy hits 82% response rate
Imugene's CAR-T therapy hits 82% response rate
Markets in a Minute: Imugene shines, AUB Group sinks
Markets in a Minute: Imugene shines, AUB Group sinks
Imugene, JW partner on CF33-CD19 for solid tumors
Imugene, JW partner on CF33-CD19 for solid tumors
ausbiz: Imugene transforms the cancer treatment landscape one trial at a time
ausbiz: Imugene transforms the cancer treatment landscape one trial at a time
Imugene Investor Webinar – CAR T naïve lymphomas & ASH Presentation | Nov 05, 2025
Imugene Investor Webinar – CAR T naïve lymphomas & ASH Presentation | Nov 05, 2025
Investor webinar – CAR T naïve lymphomas & ASH presentation
Investor webinar – CAR T naïve lymphomas & ASH presentation
Компания Imugene готовит ключевое исследование препарата Azer-Cel совместно с FDA
Компания Imugene готовит ключевое исследование препарата Azer-Cel совместно с FDA
Just the facts: Imugene, Firefly Metals, Alkane and Anteris
Just the facts: Imugene, Firefly Metals, Alkane and Anteris
Imugene Limited (ASX:IMU) presentation at Ausbiz Investor Connect October 2025
Imugene Limited (ASX:IMU) presentation at Ausbiz Investor Connect October 2025
Just the Facts: Imugene’s CAR T shines; Titan, FireFly & Aurum deliver on the quarter
Just the Facts: Imugene’s CAR T shines; Titan, FireFly & Aurum deliver on the quarter
Lymphoma Survivor Shares His Story: Breakthrough CAR-T Trial | Imugene on 7NEWS Australia
Lymphoma Survivor Shares His Story: Breakthrough CAR-T Trial | Imugene on 7NEWS Australia
Imugene’s Leslie Chong talks Azer-cel breakthrough
Imugene’s Leslie Chong talks Azer-cel breakthrough
Science Series with Imugene CMO John Byon and, Azer-cel Phase 1b trial Dr Joseph Maakaron
Science Series with Imugene CMO John Byon and, Azer-cel Phase 1b trial Dr Joseph Maakaron
Investor webinar: Azer-cel new data, July 2025
Investor webinar: Azer-cel new data, July 2025
Proactive Investors | Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Proactive Investors | Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Imugene CMO and CEO talk trial momentum and immuno-oncology progress
Imugene CMO and CEO talk trial momentum and immuno-oncology progress
Imugene CMO and CEO talk trial momentum and immuno-oncology progress
Imugene CMO and CEO talk trial momentum and immuno-oncology progress
Imugene CMO and CEO talk trial momentum and immuno-oncology progress
Imugene CMO and CEO talk trial momentum and immuno-oncology progress
Imugene (IMU) | Bell Potter Healthcare Horizons Summit 2025
Imugene (IMU) | Bell Potter Healthcare Horizons Summit 2025